Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

FITC-compatible CD19 Protein

FITC-compatible CD19 Protein

CAT#: CAR-T001

Inquiry

Overview Specification

Species	Human
Tag	C-His
Expression Systems	Expi293
Keywords	Human; C-His; Expi293

Synonyms	CD19; B4; CVID3; Leu-12; MGC12802
Background	CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% of B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
Source	FITC-Compatible Human CD19 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Pro20-Lys291.
Molecular Weight	The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	>95% as determined by Tris-Bis PAGE. >95% as determined by HPLC.
Formulation	Supplied as 0.22 μm filtered solution in PBS (pH 7.4). Please dilute to the desired concentration according to the concentration of the solution shown on the product label.
Storage	Valid for 12 months from date of receipt when stored at -80℃.
Notes	Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Online Inquiry

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.